484 related articles for article (PubMed ID: 18612536)
1. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
Folkeringa N; Coppens M; Veeger NJ; Bom VJ; Middeldorp S; Hamulyak K; Prins MH; Büller HR; van der Meer J
Thromb Haemost; 2008 Jul; 100(1):38-44. PubMed ID: 18612536
[TBL] [Abstract][Full Text] [Related]
2. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
Libourel EJ; Bank I; Meinardi JR; Baljé -Volkers CP; Hamulyak K; Middeldorp S; Koopman MM; van Pampus EC; Prins MH; Büller HR; van der Meer J
Haematologica; 2002 Oct; 87(10):1068-73. PubMed ID: 12368162
[TBL] [Abstract][Full Text] [Related]
3. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.
Brouwer JL; Lijfering WM; Ten Kate MK; Kluin-Nelemans HC; Veeger NJ; van der Meer J
Thromb Haemost; 2009 Jan; 101(1):93-9. PubMed ID: 19132194
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study.
van Vlijmen EF; Brouwer JL; Veeger NJ; Eskes TK; de Graeff PA; van der Meer J
Arch Intern Med; 2007 Feb; 167(3):282-9. PubMed ID: 17296885
[TBL] [Abstract][Full Text] [Related]
5. High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects.
Folkeringa N; Brouwer JL; Korteweg FJ; Veeger NJ; Erwich JJ; van der Meer J
Br J Haematol; 2007 Jul; 138(1):110-6. PubMed ID: 17555454
[TBL] [Abstract][Full Text] [Related]
6. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?
Linnemann B; Schindewolf M; Zgouras D; Erbe M; Jarosch-Preusche M; Lindhoff-Last E
Thromb Res; 2008; 121(6):743-50. PubMed ID: 17804043
[TBL] [Abstract][Full Text] [Related]
7. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects.
Lijfering WM; Coppens M; van de Poel MH; Middeldorp S; Hamulyák K; Bank I; Veeger NJ; Prins MH; Büller HR; van der Meer J
Thromb Haemost; 2007 Aug; 98(2):457-63. PubMed ID: 17721631
[TBL] [Abstract][Full Text] [Related]
8. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study.
Mahmoodi BK; Brouwer JL; Veeger NJ; van der Meer J
Circulation; 2008 Oct; 118(16):1659-67. PubMed ID: 18824642
[TBL] [Abstract][Full Text] [Related]
9. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification.
Brouwer JL; Veeger NJ; van der Schaaf W; Kluin-Nelemans HC; van der Meer J
Br J Haematol; 2005 Mar; 128(5):703-10. PubMed ID: 15725093
[TBL] [Abstract][Full Text] [Related]
10. The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels.
Lijfering WM; Veeger NJ; Brouwer JL; van der Meer J
Haematologica; 2007 Dec; 92(12):1703-6. PubMed ID: 18055997
[TBL] [Abstract][Full Text] [Related]
11. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
[TBL] [Abstract][Full Text] [Related]
12. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study.
Bank I; van de Poel MH; Coppens M; Hamulyák K; Prins MH; van der Meer J; Veeger NJ; Büller HR; Middeldorp S
Thromb Haemost; 2007 Nov; 98(5):1040-4. PubMed ID: 18000609
[TBL] [Abstract][Full Text] [Related]
13. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
14. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
15. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism.
Kraaijenhagen RA; in't Anker PS; Koopman MM; Reitsma PH; Prins MH; van den Ende A; Büller HR
Thromb Haemost; 2000 Jan; 83(1):5-9. PubMed ID: 10669145
[TBL] [Abstract][Full Text] [Related]
16. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study.
Bank I; Libourel EJ; Middeldorp S; Van Pampus EC; Koopman MM; Hamulyák K; Prins MH; Van Der Meer J; Büller HR
Arch Intern Med; 2004 Sep; 164(17):1932-7. PubMed ID: 15451770
[TBL] [Abstract][Full Text] [Related]
17. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
[TBL] [Abstract][Full Text] [Related]
18. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.
Santamaría A; Martínez-Rubio A; Borrell M; Mateo J; Ortín R; Fontcuberta J
Haematologica; 2004 Jul; 89(7):880-1. PubMed ID: 15257950
[TBL] [Abstract][Full Text] [Related]
19. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
Couturaud F; Duchemin J; Leroyer C; Delahousse B; Abgrall JF; Mottier D;
Thromb Haemost; 2008 Jan; 99(1):223-8. PubMed ID: 18217158
[TBL] [Abstract][Full Text] [Related]
20. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
